4- (2- (2- chloro- 4- ((5- cyclopropyl- 3- (2,6- dichlorophenyl)- 4- isoxazolyl)methoxy)phenyl)cyclopropyl)benzoic acid

a farnesoid X receptor agonist; structure in first source

Also Known As:

PX20606

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Benzoates: 426
        4-(2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)cyclopropyl)benzoic acid: 2
- Carboxylic Acids: 973
  - Carbocyclic Acids
    - Benzoates: 426
      - 4-(2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)cyclopropyl)benzoic acid: 2
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Isoxazoles: 155
      - 4-(2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)cyclopropyl)benzoic acid: 2

Experts

1.	Burnet, Michael: 2 articles (01/2017 - 12/2012)
2.	Deuschle, Ulrich: 2 articles (01/2017 - 12/2012)
3.	Hambruch, Eva: 2 articles (01/2017 - 12/2012)
4.	Kremoser, Claus: 2 articles (01/2017 - 12/2012)
5.	Garnys, Lukas: 1 article (01/2017)
6.	Hayden, Hubert: 1 article (01/2017)
7.	Mitteregger, Dieter: 1 article (01/2017)
8.	Oberhuber, Georg: 1 article (01/2017)
9.	Peck-Radosavljevic, Markus: 1 article (01/2017)
10.	Podesser, Bruno K: 1 article (01/2017)

Related Diseases

1.	Portal Hypertension 01/01/2017 - "The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction." 01/01/2017 - "The non-steroidal FXR agonist PX20606 ameliorates portal hypertension by reducing liver fibrosis, vascular remodelling and sinusoidal dysfunction. " 01/01/2017 - "The impact of the novel non-steroidal and selective FXR agonist PX20606 on portal hypertension and fibrosis was explored in this study. " 01/01/2017 - "In experimental models of non-cirrhotic (partial portal vein ligation, PPVL, 7days) and cirrhotic (carbon tetrachloride, CCl4, 14weeks) portal hypertension, PX20606 (PX,10mg/kg) or the steroidal FXR agonist obeticholic acid (OCA,10mg/kg) were gavaged. "
2.	Liver Cirrhosis (Hepatic Cirrhosis) 01/01/2017 - "The non-steroidal FXR agonist PX20606 ameliorates portal hypertension by reducing liver fibrosis, vascular remodelling and sinusoidal dysfunction. "
3.	Hypertension (High Blood Pressure) 01/01/2017 - "Thus, PX20606 leads to an improved blood flow through the liver and decreases hypertension of the portal vein. "
4.	Fibrosis (Cirrhosis) 01/01/2017 - "The impact of the novel non-steroidal and selective FXR agonist PX20606 on portal hypertension and fibrosis was explored in this study. "
5.	Atherosclerotic Plaque (Atheroma) 12/01/2012 - "In CETPtg-LDLR(-/-) mice PX20606 potently lowered total cholesterol and, despite the observed HDL cholesterol (HDLc) reduction, caused a highly significant decrease in atherosclerotic plaque size. "

Related Drugs and Biologics

1.	HDL Cholesterol
2.	Cholesterol
3.	Carbon Tetrachloride (Tetrachloromethane)
4.	Bile Acids and Salts (Bile Acids)
5.	obeticholic acid

Related Therapies and Procedures

1.	Ligation